Raymond James & Associates Lannett CO Inc Transaction History

Raymond James & Associates

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 21, 2020	SELL	$6.36 - $10.05 $81,598 - $128,941	-12,830 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$8.49 - $12.81 $108,926 - $164,352	12,830 New	12,830 $113,000
Q3 2018 Nov 14, 2018	SELL	$4.75 - $14.5 $181,644 - $554,494	-38,241 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$13.3 - $17.45 $325,318 - $426,827	-24,460 Reduced 39.01%	38,241 $520,000
Q1 2018 May 14, 2018	SELL	$14.7 - $24.95 $30,429 - $51,646	-2,070 Reduced 3.2%	62,701 $1.01 Million
Q4 2017 Feb 14, 2018	SELL	$19.9 - $29.25 $57,928 - $85,146	-2,911 Reduced 4.3%	64,771 $1.5 Million
Q3 2017 Nov 13, 2017	SELL	$15.1 - $19.25 $226,802 - $289,135	-15,020 Reduced 18.16%	67,682 $1.25 Million
Q2 2017 Aug 14, 2017	BUY	N/A	82,702	82,702 $1.69 Million

Ticker LCI
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,960,000
Market Cap $1.29M
Description
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nas...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.